HK1189509A1 - 利用紅外區域光的光動力的治療劑或診斷劑 - Google Patents

利用紅外區域光的光動力的治療劑或診斷劑

Info

Publication number
HK1189509A1
HK1189509A1 HK14102770.6A HK14102770A HK1189509A1 HK 1189509 A1 HK1189509 A1 HK 1189509A1 HK 14102770 A HK14102770 A HK 14102770A HK 1189509 A1 HK1189509 A1 HK 1189509A1
Authority
HK
Hong Kong
Prior art keywords
infrared
diagnostic agent
photodynamic therapy
spectrum light
spectrum
Prior art date
Application number
HK14102770.6A
Other languages
English (en)
Inventor
湯淺英哉
小倉俊郎
高橋究
井上克司
田中徹
Original Assignee
國立大學法人東京工業大學
思佰益藥業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立大學法人東京工業大學, 思佰益藥業股份有限公司 filed Critical 國立大學法人東京工業大學
Publication of HK1189509A1 publication Critical patent/HK1189509A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK14102770.6A 2011-05-06 2014-03-19 利用紅外區域光的光動力的治療劑或診斷劑 HK1189509A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011103816 2011-05-06
PCT/JP2012/002939 WO2012153493A1 (ja) 2011-05-06 2012-04-27 赤外域光による光線力学的治療又は診断剤

Publications (1)

Publication Number Publication Date
HK1189509A1 true HK1189509A1 (zh) 2014-06-13

Family

ID=47138982

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14102770.6A HK1189509A1 (zh) 2011-05-06 2014-03-19 利用紅外區域光的光動力的治療劑或診斷劑

Country Status (6)

Country Link
US (1) US9757357B2 (zh)
EP (1) EP2705855B1 (zh)
JP (1) JP5854407B2 (zh)
CN (1) CN103491980B (zh)
HK (1) HK1189509A1 (zh)
WO (1) WO2012153493A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8777898B2 (en) 2011-01-31 2014-07-15 Boston Scientific Scimed, Inc. Medical devices having releasable coupling
CN103028197B (zh) * 2012-12-31 2016-10-05 波纳维科（天津）医疗科技有限公司 一种医用a型红外线治疗设备
CN103869063B (zh) * 2014-03-21 2016-03-30 合肥工业大学 强抗基质干扰型双酚a上转换荧光层析试纸条的制备方法
US9956426B2 (en) * 2015-02-26 2018-05-01 Amol Punjabi Upconverting nanoparticles
JPWO2016158195A1 (ja) * 2015-03-31 2018-01-25 ソニー株式会社 光照射方法、光照射装置、光照射システム、光線力学診断用又は光線力学治療用装置システム、腫瘍部位特定システム及び腫瘍治療システム
CN106309366B (zh) * 2016-09-19 2018-10-16 天津大学 一种用于光动力治疗的聚苯乙烯-聚丙烯酸纳米载药微球的制备方法
EP3773561A4 (en) 2018-03-26 2021-11-24 Zamadar, Matibur Rahaman MULTIFUNCTIONAL TREATMENT AND DIAGNOSTIC COMPOSITIONS AND PROCEDURES
CN114790391A (zh) * 2022-04-14 2022-07-26 湖南科技大学 一种基于配体氧化的油酸封端上转换纳米颗粒的亲水性修饰方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2793832B2 (ja) 1989-04-05 1998-09-03 オリンパス光学工業株式会社 癌治療装置
WO2005087196A1 (ja) * 2004-03-17 2005-09-22 Tokai University Educational System 免疫応答システムを利用したドラッグデリバリーシステム
JP2007186580A (ja) 2006-01-12 2007-07-26 Fujifilm Corp 重合体粒子、蛍光性重合体微粒子、重合体微粒子の製造方法、蛍光性重合体微粒子の製造方法、蛍光検出キット及び蛍光検出方法
JP2009024115A (ja) 2007-07-21 2009-02-05 Tokyo Univ Of Science 蛍光体微粒子−有機色素複合体、及び当該複合体からなる光線力学的治療剤
WO2009061406A1 (en) * 2007-11-05 2009-05-14 The Trustees Of Princeton University Nanoparticles for photodynamic therapy
EP3056497B1 (en) * 2008-05-05 2018-08-29 The General Hospital Corporation Methods using bodipy-labelled enzyme substrates
KR101050401B1 (ko) * 2008-05-09 2011-07-19 경북대학교 산학협력단 이중 방식 ｐｅｔ／ｍｒ 조영제
JP2010053079A (ja) * 2008-08-28 2010-03-11 Toin Gakuen ５−アミノレブリン酸誘導体及びその塩

Also Published As

Publication number Publication date
CN103491980A (zh) 2014-01-01
JP5854407B2 (ja) 2016-02-09
EP2705855B1 (en) 2018-06-13
EP2705855A4 (en) 2014-11-26
JPWO2012153493A1 (ja) 2014-07-31
EP2705855A1 (en) 2014-03-12
US9757357B2 (en) 2017-09-12
US20140056817A1 (en) 2014-02-27
WO2012153493A1 (ja) 2012-11-15
CN103491980B (zh) 2016-04-13

Similar Documents

Publication Publication Date Title
EP3263066B8 (en) Intra-oral light therapy apparatus
GB2493100B (en) Combination photodynamic devices
EP2827818A4 (en) LASER FOR PHOTODYNAMIC THERAPY
ZA201305897B (en) Combination therapy
EP2850061A4 (en) HALOGENATED COMPOUNDS FOR PHOTODYNAMIC THERAPY
HK1205900A1 (zh) 具備准直器的光動力學診斷裝置
HK1189509A1 (zh) 利用紅外區域光的光動力的治療劑或診斷劑
ZA201400120B (en) Combination therapy
GB2496805B (en) Compounds for photodynamic therapy
EP2537530A4 (en) RADIOTHERAPY AGENT
EP2727603A4 (en) PHOTODYNAMIC THERAPY USING PHOTOSENSITIZING AGENT OR 5-AMINOLEVULINIC ACID
HK1197178A1 (zh) 組合 療法
HK1207013A1 (zh) 用於光動力療法的導管
PL2723330T3 (pl) Lek kombinowany zawierający środek naczynioskurczowy
EP2701744A4 (en) COMBINATION THERAPY
PL2729173T3 (pl) Terapia nacelowana na egfr
IL228346A0 (en) Photodynamically focused treatment methods
GB201109133D0 (en) Photodynamic therapy
GB201210016D0 (en) Photodynamic therapy
GB201222544D0 (en) Photodynamic therapy and diagnosis
GB201210019D0 (en) Delivery mechanism for photodynamic therapy
GB201114226D0 (en) Combination therapy
GB201102694D0 (en) Laser therapy
GB201110268D0 (en) Delivery mechanism for photodynamic therapy
AU2011904279A0 (en) Combination Therapy